NCT06499285 2026-03-11
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06351631 2026-02-20
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06093672 2026-01-27
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT04064060 2025-11-12
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
Phase 3 Recruiting
NCT06468033 2025-08-13
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia
Phase 3 Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT05991908 2025-02-18
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT04116502 2024-11-18
MITHRIDATE
University of Birmingham
Phase 3 Recruiting
NCT04655092 2024-11-08
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PharmaEssentia Japan K.K.
Phase 3 Recruiting
NCT03459534 2024-10-28
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Phase 3 Recruiting
NCT05753384 2024-07-29
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital
Phase 3 Recruiting